Back to news

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

PR Newswire•16/11/2026•18:00 ET
0

Key Highlights

  • ➤Five-year continuous treatment produced a −2.05-point CDR-SB difference versus ADNI decline
  • ➤Lecanemab reduced relative risk of next-stage disease progression by 36% versus ADNI
  • ➤Lecanemab cut relative risk of moderate/severe AD progression by 49% versus ADNI
  • ➤Low-tau patients: 62% showed CDR-SB improvement after five years
  • ➤ARIA-E incidence declined from 13.5% in year one to 0.6% in year five

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026 PR Newswire

Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in